IP Library Granted Patent US 10,470,885
Granted Patent B2
US 10,470,885 · App. 13/699,090 · Granted Nov 12, 2019

Implant for cartilage repair

Inventors: Nina Bake (Lidingö, SE); Leif Ryd (Stockholm, SE)
Assignee: EPISURF IP-MANAGEMENT AB
A61F2/28B33Y80/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,470,885
App. No.
13/699,090
Granted
Nov 12, 2019
Kind
B2
Abstract

A medical implant for cartilage repair at an articulating surface of a joint includes a contoured, substantially plate shaped, implant body and at least one extending post. The implant body has an articulate surface configured to face the articulating part of the joint and a bone contact surface configured to face the bone structure of a joint, where the articulate and bone contact surfaces face mutually opposite directions and the bone contact surface is provided with the extending post. A cartilage contact surface connects the articulate and the bone contact surfaces and is configured to contact the cartilage surrounding the implant body in a joint. The cartilage contact surface has a coating that substantially only includes a bioactive material.

Claims (21)

1. A medical implant for cartilage repair at an articulating surface of a joint, comprising:

a single, integral piece comprising a contoured, substantially plate shaped, implant body portion and at least one extending post portion,

wherein said implant body portion has:

a) an articulating surface configured to face the articulating part of the joint;

b) a bone contact surface configured to face the bone structure of a joint, said articulating and bone contact surfaces facing mutually opposite directions; and

c) a cartilage contact surface, connecting the articulating and the bone contact surfaces, which is configured to contact the cartilage surrounding the implant body portion in a joint,

wherein 60-100% of the cartilage contact surface is coated with a material consisting essentially of hydroxyapatite or 60-100% of the cartilage contact surface is coated with a double coating, wherein the double coating comprises an inner coating of titanium and a surface coating consisting essentially of hydroxyapatite,

wherein the at least one extending post portion joins the implant body portion at the bone contact surface, and

wherein said implant is not made of porous material.

2. The medical implant of claim 1 , wherein the coating on the cartilage contact surface is capable of stimulating cartilage growth and regeneration.

3. The medical implant according according to claim 2 , wherein said coating on the cartilage contact surface is hydroxyapatite.

4. The medical implant of claim 1 , wherein said coating on the cartilage contact surface consists of 95-99.5% hydroxyapatite according to X-ray diffraction.

5. The medical implant according to claim 1 , wherein said bone contact surface is coated or partly coated with bioactive material.

6. The medical implant according to claim 5 , wherein said bioactive material of the bone contact surface is any of hydroxyapatite, titanium, bone morphogenetic protein, beta tricalcium phosphate, collagens, fibronectin, osteonectin, calcium sulphate, calcium phosphate, calcium aluminates, calcium silicates, calcium carbonates, bioactive glass or bisphosphonates, or combinations thereof.

7. The medical implant according to claim 5 , wherein the coating of the bone contact surface consists of more than 95% hydroxyapatite according to X-ray diffraction.

8. The medical implant according to claim 1 , wherein said extending post portion is coated or partly coated with bioactive material.

9. The medical implant according to claim 8 , wherein said bioactive material of the extending post portion is any of hydroxyapatite, titanium, bone morphogenetic protein, beta tricalcium phosphate, collagens, fibronectin, osteonectin, calcium sulphate, calcium phosphate, calcium aluminates, calcium silicates, calcium carbonates, bioactive glass or bisphosphonates, or combinations thereof.

10. The medical implant according to claim 8 , wherein the coating of the extending post portion consists of more than 95% hydroxyapatite according to X-ray diffraction.

11. The medical implant according to claim 1 , wherein said extending post portion is not coated with bioactive material.

12. The medical implant according to claim 1 , wherein said coating on the cartilage contacting surface consists of more than 95% hydroxyapatite according to X-ray diffraction.

13. The medical implant according to claim 1 , wherein the bone contact surface has a double coating, wherein the double coating comprises an inner coating of titanium and a surface coating of hydroxyapatite and/or tricalcium phosphate.

Assignments (3)
CHANGE OF ADDRESS Recorded Sep 25, 2018
From: EPISURF IP-MANAGEMENT AB
To: EPISURF IP-MANAGEMENT AB
Reel/Frame 047570/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2013
From: EPISURF MEDICAL AB
To: EPISURF IP-MANAGEMENT AB
Reel/Frame 030671/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2013
From: BAKE, NINA; RYD, LEIF
To: EPISURF MEDICAL AB
Reel/Frame 029649/0848 →
Priority Claims (1)
EP 10163721.3 · May 24, 2010 · regional
Continuity (2)
Provisional Application 61347650 · May 24, 2010
Related Publication 20130110252A1 · May 2, 2013
Cited By (1)
US 12,642,539